A vital program to the survival of the country’s most vulnerable hospitals has announced a change that could significantly impact eligible hospitals. For more than 30 years, the 340B Drug Pricing Program has been an upfront discount model to hospitals and health systems. In August, HRSA announced a 340B Rebate Model Pilot Program proposed to take effect in 2026. The purpose of the program is to allow specific manufacturers to use a rebate model instead of upfront discounts for a select group of 340B drugs, requiring hospitals and health systems to pay upfront for these vital medications. This will create a significant cash strain for hospitals.
In this webinar, you’ll learn what this new program means for hospitals, including:
- Details on the cashflow drain for hospitals as 340B entities will pay the wholesale acquisition cost (WAC) for covered medications upfront and then submit claims data to receive a rebate
- How hospitals can prepare for this program change – financially and operationally
- Why subject matter expertise is vital in ensuring hospitals are monitoring the status of this program, protecting themselves by understanding the safeguards and projecting the incremental monthly increase in drug costs following launch of the pilot
- How to utilize experts to optimize current pharmacy programs and offset the repercussions of the new rebate model
